President Srdjan R. Stankovic to retire Dec 31, 2022; will remain as consultant

ACADIA PHARMACEUTICALS INC

Srdjan R. Stankovic notified Acadia of his retirement as President, effective Dec 31, 2022.
He will continue in his current role through Dec 31 and then serve as consultant and advisor.
No replacement President has been announced.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Srdjan R. Stankovic

President

ACAD · ACADIA PHARMACEUTICALS INC

Effective: 2022-12-31
Filed: October 28, 2022, 7:59 PM ET

On October 27, 2022, Srdjan R. Stankovic, M.D., M.S.P.H., notified Acadia Pharmaceuticals Inc. (the “Company”) of his intention to retire as the Company’s President, effective December 31, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Srdjan R. Stankovic departed as President at ACADIA PHARMACEUTICALS INC.

Action: retire
Role: President

Exact text from the filing

On October 27, 2022, Srdjan R. Stankovic, M.D., M.S.P.H., notified Acadia Pharmaceuticals Inc. (the “Company”) of his intention to retire as the Company’s President, effective December 31, 2022.

View on SEC.gov

ACADIA PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001193125-22-272491

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.